Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.32 -3.22%

-$0.14 today

Market cap
$192.16M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.42M

Average 0.38M

Returns on capital

Prelude Therapeutics Incorporated management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-145.0%

avg -37.2%

ROIC

-114.8%

avg -82.1%

ROA

-70.4%

avg -64.6%

Analysis

ROA is currently the strongest return metric at -70.4% versus its period average of -64.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Krishna Vaddi

Founder, Chief Executive Officer & DirectorUSD 935.26K60837.00K1.07%

Bryant David Lim

Chief Financial Officer, Chief Legal Officer & Corporate SecretaryUSD 681.05K55275.00K0.35%

Peggy A. Scherle

Chief Scientific OfficerUSD 674.21K64——

Andrew Combs

Executive Vice President & Chief Chemistry OfficerUSD 562.46K59230.00K0.29%

Wan-Jen Hong

Senior Vice President of Clinical Development—47——

Michele Porreca

Chief People Officer————

Madhu Pudipeddi

Senior Vice President of Technical Operations————

Naveen Babbar

Senior Vice President of Translation Medicine————

Robert A. Doody Jr.

Senior Vice President of Investor Relations————

Aimee Crombie

Senior Vice President and Head of Strategic Planning & Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 4, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

6

$25.00M

Sells

0

$0.00

Net Transaction Value

+$25.00M

Net buying

Most Active

Bonita David P

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 21, 26

Bonita David P

Indirect

Buy$7.5M
Apr 21, 26

Bonita David P

Indirect

Buy$5M
Apr 21, 26

ORBIMED ADVISORS LLC

Indirect

Buy$7.5M
Apr 21, 26

ORBIMED ADVISORS LLC

Indirect

Buy$5M
Apr 21, 26

BAKER BROS. ADVISORS LP

Indirect

Buy$213.8
Apr 21, 26

BAKER BROS. ADVISORS LP

Indirect

Buy$11.5

Summary

Insiders reported 6 buys worth $25.00M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $25.00M. Bonita David P was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+52.5% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Forward estimates point to Revenue at +52.5% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Prelude Therapeutics Incorporated compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PRLD's management, answered from reported figures.

Who manages PRLD?

Prelude Therapeutics Incorporated (PRLD) lists 10 active executives. The top listed executive is Wan-Jen Hong, Senior Vice President of Clinical Development.

Are PRLD insiders buying or selling?

Recent insider activity shows net buying of $66.92M.